"ADP-ribosyl Cyclase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
| Descriptor ID |
D051997
|
| MeSH Number(s) |
D08.811.277.450.430.400.060.500 D12.776.543.550.045
|
| Concept/Terms |
ADP-ribosyl Cyclase 1- ADP-ribosyl Cyclase 1
- 1, ADP-ribosyl Cyclase
- ADP ribosyl Cyclase 1
- Cyclase 1, ADP-ribosyl
- T10 Antigen
- Antigen, T10
- NIM-R5 Antigen
- NIM R5 Antigen
- CD38 Antigens
- ADPR Cyclase T10
- Cyclase T10, ADPR
- Acute Lymphoblastic Leukemia Cells Antigen CD38
- Lymphocyte Differentiation Antigen CD38
- Antigens, CD38
- CD38 Antigen
- ADPR Cyclase CD38
- CD38, ADPR Cyclase
- Cyclase CD38, ADPR
|
Below are MeSH descriptors whose meaning is more general than "ADP-ribosyl Cyclase 1".
Below are MeSH descriptors whose meaning is more specific than "ADP-ribosyl Cyclase 1".
This graph shows the total number of publications written about "ADP-ribosyl Cyclase 1" by people in this website by year, and whether "ADP-ribosyl Cyclase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2006 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "ADP-ribosyl Cyclase 1" by people in Profiles.
-
CD38: T Cell Immuno-Metabolic Modulator. Cells. 2020 07 17; 9(7).
-
CD38-NAD+-Sirt1 axis in T cell immunotherapy. Aging (Albany NY). 2019 10 23; 11(20):8743-8744.
-
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019 09; 33(9):2266-2275.
-
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. Cell Metab. 2018 01 09; 27(1):85-100.e8.
-
Increased Natural Killer Cell Activation in HIV-Infected Immunologic Non-Responders Correlates with CD4+ T Cell Recovery after Antiretroviral Therapy and Viral Suppression. PLoS One. 2017; 12(1):e0167640.
-
CD38 Expression in a Subset of Memory T Cells Is Independent of Cell Cycling as a Correlate of HIV Disease Progression. Dis Markers. 2016; 2016:9510756.
-
Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. Biochem Biophys Res Commun. 2006 Oct 13; 349(1):353-9.
-
Regulation of intracellular levels of NAD: a novel role for CD38. Biochem Biophys Res Commun. 2006 Jul 14; 345(4):1386-92.
-
Human cord blood long-term engrafting cells are CD34+ CD38-. Leukemia. 2003 May; 17(5):960-4.
-
CD38 expression by hematopoietic stem cells of newborn and juvenile mice. Leukemia. 2003 Jan; 17(1):171-4.